These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15573900)

  • 1. [Efficacy and safety of levofloxacin in low respiratory tract infection].
    Zubkov MN
    Antibiot Khimioter; 2004; 49(5):31-7. PubMed ID: 15573900
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
    Iakovlev VP; Svetukhin AM; Blatun LA; Ukhin SA
    Antibiot Khimioter; 2004; 49(8-9):57-65. PubMed ID: 15727148
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of levofloxacin in the treatment of respiratory tract infection.
    Shah PM
    J Chemother; 2000 Oct; 12 Suppl 4():27-31. PubMed ID: 11131957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in Lebanon: a report of three cases.
    Naba MR; Araj GF; Baban TA; Tabbarah ZA; Awar GN; Kanj SS
    J Infect Public Health; 2010; 3(3):113-7. PubMed ID: 20869671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
    Fuller JD; Low DE
    Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.
    Wang H; Chen M; Xu Y; Sun H; Yang Q; Hu Y; Cao B; Chu Y; Liu Y; Zhang R; Yu Y; Sun Z; Zhuo C; Ni Y; Hu B; Tan TY; Hsueh PR; Wang JH; Ko WC; Chen YH; Wahjono H
    Int J Antimicrob Agents; 2011 Nov; 38(5):376-83. PubMed ID: 21880469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin.
    Fogarty C; Goldschmidt R; Bush K
    Clin Infect Dis; 2000 Aug; 31(2):613-5. PubMed ID: 10987733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
    Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y
    Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Davidson R; Cavalcanti R; Brunton JL; Bast DJ; de Azavedo JC; Kibsey P; Fleming C; Low DE
    N Engl J Med; 2002 Mar; 346(10):747-50. PubMed ID: 11882730
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
    Wise R; Andrews JM
    J Chemother; 1998 Aug; 10(4):276-9. PubMed ID: 9720464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV; Iakovlev VP
    Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antimicrobial effect of levofloxacin].
    Mitrokhin SD
    Antibiot Khimioter; 2003; 48(11):23-30. PubMed ID: 15106308
    [No Abstract]   [Full Text] [Related]  

  • 14. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
    Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
    BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levofloxacin and other antibacterial drugs].
    Ivanov DV; Budanov SV
    Antibiot Khimioter; 2006; 51(6):27-37. PubMed ID: 17523419
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.
    Uria-Nickelsen M; Neckermann G; Sriram S; Andrews B; Manchester JI; Carcanague D; Stokes S; Hull KG
    Int J Antimicrob Agents; 2013 Apr; 41(4):363-71. PubMed ID: 23305654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levofloxacin in patients with severe respiratory tract infection.
    Odagiri S
    Drugs; 1995; 49 Suppl 2():426-7. PubMed ID: 8549387
    [No Abstract]   [Full Text] [Related]  

  • 18. [The present and future of levofloxacin in the treatment of respiratory infections].
    García-Rodríguez JA; Muñoz Bellido JL; Alonso Manzanares MA; Gutiérrez Zufiaurre MN
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():53-8. PubMed ID: 10563113
    [No Abstract]   [Full Text] [Related]  

  • 19. [Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections].
    Płusa T
    Pol Merkur Lekarski; 2011 Feb; 30(176):91-6. PubMed ID: 21544977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Hutchinson J
    N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12102064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.